TopFunds

Steris

NYSE: STE

Stock price

210.76 USD

(-3.98%) 5 years

Health Care EquipmentMedical - Devices

Financial Performance

Share

5Y price score: (5)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 217.4%

DATE RANGE:

%

ㅤ

  • Earnings per share

  • Free cash flow per share

  • Stock price

Time scale:

By default your notes are visible only to you.

195.1

52-week range

269.4

210.76

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

4.5 %

Dividend Yield TTM

1.2 %

Market cap $

$ 20,540

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

25.8

Price / Book TTM

2.9

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

0.9

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(12.1) %

0.3 %

217.4 %

Free cash flow per share growth

(13.6) %

87.9 %

446.8 %

Earnings per share growth

14 %

71.3 %

408.3 %

Founded: 1,985

Employees: 18,000

Business Summary:STERIS plc operates as a global provider, delivering a wide array of products and services crucial for infection prevention and various procedural needs. The company's operations are strategically divided into four primary segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare division offers a comprehensive suite of solutions, encompassing specialized cleaning chemicals and sterility assurance products. It also provides automated systems for endoscope reprocessing and tracking, alongside critical capital equipment for sterile processing departments, such as washers, sterilizers, and accessories for gastrointestinal (GI) procedures. Additionally, this segment furnishes essential operating room equipment, including surgical tables, lighting, and connectivity solutions. Beyond products, the Healthcare division offers extensive support services, which include equipment management, installation, maintenance, upgrades, repairs, and troubleshooting for capital assets. It also delivers preventive maintenance programs, general repair services, and specialized instrument and endoscope repair. Furthermore, the division provides tailored consulting for process improvement and manages outsourced sterile processing services for instruments. The Applied Sterilization Technologies segment specializes in offering outsourced sterilization and testing services. These are provided to manufacturers of medical devices and pharmaceuticals through its expansive network of approximately 50 dedicated contract sterilization and laboratory facilities. In the Life Sciences sector, STERIS focuses on the design, production, and sale of consumable items. These include formulated cleaning chemistries, barrier and sterility assurance products, various sterilizers (both steam and vaporized hydrogen peroxide), and washer disinfectors. This segment also provides equipment installation, maintenance, upgrades, repairs, and troubleshooting, in addition to preventive maintenance programs. Finally, the Dental segment caters to dental practices by supplying a range of hand and powered dental instruments, infection control solutions, personal protective equipment (PPE), and products designed to maintain water quality within dental suites. STERIS's diverse portfolio of products and services reaches a broad clientele, including hospitals, other healthcare institutions, and pharmaceutical manufacturers. Established in 1985, STERIS plc maintains its corporate headquarters in Dublin, Ireland.

Q&A

SEARCH
Get answers on financials, industry, fundamentals or other questions.

Contribute

By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more

VIEW ALL Q&A

Contribute or ask questions about business following TopFunds community guidelines

Fair Value Reference Estimate

Latest Earnings Call Takeaways

2027 Q1 (Aug 6, 2026)

1) Strategy & Leadership
- STERIS is maintaining its original fiscal 2027 outlook, projecting as-reported revenue growth of 7%-8% and constant currency organic revenue growth of 6%-7%.
- The company announced a $600 million investment to build a new Formulated Chemistry Center of Excellence in North Carolina, aimed at enhancing manufacturing capabilities and supporting growth in high-margin products.
- The facility is expected to be operational in two to three years, with a phased approach to opening.

2) Financial & Segment Results
- Total revenue grew 7% YoY, with constant currency organic revenue growth of 6% driven by volume and pricing.
- Gross margin improved to 46%, up 70 basis points YoY, while EBIT margin increased to 23.8%, reflecting operational discipline and favorable currency effects.
- Adjusted net income was $253.4 million, with earnings per diluted share at $2.59, an 11% increase YoY.
- Free cash flow decreased to $279.6 million, down from $326.5 million in the prior year, primarily due to lower working capital contributions.

3) Operational Insights & Product Plans
- The Healthcare segment saw 6% constant currency organic revenue growth, with services growing 10% and consumables 9%.
- The Life Sciences group reported 8% organic revenue growth, driven by a 17% increase in capital equipment sales.
- The company is experiencing strong demand in endoscopy, with share gains noted in both equipment and consumables.
- A restructuring program is anticipated to incur $55 million-$70 million in pretax charges, with benefits expected from the new facility's consolidation and modernization.

4) Problems / Headwinds
- The AST segment faced challenges with 5% organic revenue growth, attributed to soft global demand and inventory destocking. EBIT margins decreased to 48%, impacted by increased depreciation and lower productivity.
- Tariff costs were $14 million, slightly higher than the previous year's $12 million, although net tariffs were favorable by $2 million due to refunds.

5) Guidance & Outlook / Investor Angle
- The company expects fiscal 2027 earnings per share to be in the range of $11.10-$11.30, reflecting 9%-11% growth over fiscal 2026.
- Free cash flow is projected to be $800 million, despite the additional capital spending related to the new facility.
- The investment in North Carolina is expected to generate a return on invested capital (ROIC) of over 10% within three to five years of opening.

Bottom line: STERIS is positioned for steady growth with a solid outlook for fiscal 2027, bolstered by strategic investments and strong performance in key segments, despite facing some operational headwinds in the AST segment.

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20262025202420232022202120202019

Steris — Financial Overview, Stock Price, Market Cap

Steris is a company. Founded in 1985. As of October 9, 2026, the company's market capitalization is $20540184852 with a current stock price of $210.76.